NADAC acquisition cost data for ORIAHNN 300-1-0.5 MG/300 MG CAPS. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00074101756 | $18.08 | 2022-01-14 | Rx |
| 00074101756 | $18.08 | 2022-01-14 | Rx |
| 00074101756 | $18.08 | 2022-01-14 | Rx |
| 00074101756 | $18.08 | 2022-01-14 | Rx |
| 00074101756 | $18.08 | 2022-01-14 | Rx |
| 00074101756 | $18.08 | 2022-01-14 | Rx |
| 00074101756 | $18.08 | 2022-01-14 | Rx |
| 00074101756 | $18.08 | 2022-01-14 | Rx |
| 00074101756 | $18.08 | 2022-01-14 | Rx |
| 00074101756 | $18.08 | 2022-01-14 | Rx |
Generic: Elagolix/Estradiol/Norethindrn | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | $17.0K | 18 | 11 | $16.91 |
| 2021 | $236.8K | 210 | 72 | $17.92 |
| 2022 | $448.5K | 375 | 86 | $19.56 |
| 2023 | $404.0K | 317 | 66 | $20.60 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $50.5K | 42 | N/A |
| New York | $37.6K | 23 | N/A |
| Indiana | $35.0K | 30 | N/A |
| Texas | $34.8K | 27 | N/A |
| Louisiana | $29.0K | 25 | N/A |
| Florida | $25.9K | 20 | N/A |
| North Carolina | $25.7K | 23 | N/A |
| Georgia | $24.8K | 21 | N/A |
| Tennessee | $15.6K | 13 | N/A |
| Ohio | $14.2K | 13 | N/A |
| New Jersey | $14.1K | 12 | N/A |
| Puerto Rico | $13.4K | 12 | N/A |
| Kansas | $6.5K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.